stockrowAdaptive Biotechnologies Corporation (ADPT) vs NeoGenomics, Inc. (NEO)
- Adaptive Biotechnologies Corporation ADPT 28.00 +4.36%
- NeoGenomics, Inc. NEO 16.89 +2.43%
Adaptive Biotechnologies Corporation and NeoGenomics, Inc. are both Diagnostics & Research companies. Adaptive Biotechnologies Corporation is the larger, with a market value of $4.3B against $2.1B — 2.0× the size. Adaptive Biotechnologies Corporation grew revenue faster over the last twelve months: 17.9% against 11.1%. NeoGenomics, Inc. has the higher net margin (−4.10% vs −23.7%) and the lower return on invested capital (−2.97% vs 0.00%). Across the 18 metrics below, Adaptive Biotechnologies Corporation leads on 9 and NeoGenomics, Inc. on 9.
Valuation
Profitability
| Metric | ADPT | NEO | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 74.15% | 44.77% | 48.32% |
| Operating margin | (16.18%) | (6.27%) | (5.68%) |
| Net margin | (23.66%) | (4.10%) | (4.10%) |
| Free cash flow margin | (2.96%) | (3.37%) | 0.00% |
| Return on equity | (36.34%) | (3.94%) | 0.00% |
| Return on assets | (12.02%) | (2.35%) | (6.05%) |
| Return on invested capital | 0.00% | (2.97%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack